🚀 VC round data is live in beta, check it out!
BioStem Technologies Valuation Multiples
Discover revenue and EBITDA valuation multiples for BioStem Technologies and similar public comparables like aTyr Pharma, Valerio Therapeutics, Pliant Therapeutics, Dicot Pharma and more.
BioStem Technologies Overview
About BioStem Technologies
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AmnioWrap2.
Founded
2006
HQ
Employees
20
Website
Financials (LTM)
EV
$60M
BioStem Technologies Financials
BioStem Technologies reported last 12-month revenue of $47M.
In the same LTM period, BioStem Technologies generated had net loss of ($7M).
Revenue (LTM)
BioStem Technologies P&L
In the most recent fiscal year, BioStem Technologies reported revenue of $302M and EBITDA of $31M.
BioStem Technologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $47M | XXX | $302M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $288M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 95% | XXX | XXX | XXX |
| EBITDA | — | XXX | $31M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 10% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 10% | XXX | XXX | XXX |
| Net Profit | ($7M) | XXX | $32M | XXX | XXX | XXX |
| Net Margin | (14%) | XXX | 11% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BioStem Technologies Stock Performance
BioStem Technologies has current market cap of $84M, and enterprise value of $60M.
Market Cap Evolution
BioStem Technologies' stock price is $4.97.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $60M | $84M | 0.0% | XXX | XXX | XXX | $1.89 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioStem Technologies Valuation Multiples
BioStem Technologies trades at 1.3x EV/Revenue multiple, and 1.9x EV/EBITDA.
EV / Revenue (LTM)
BioStem Technologies Financial Valuation Multiples
As of April 20, 2026, BioStem Technologies has market cap of $84M and EV of $60M.
Equity research analysts estimate BioStem Technologies' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioStem Technologies has a P/E ratio of (12.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $84M | XXX | $84M | XXX | XXX | XXX |
| EV (current) | $60M | XXX | $60M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 1.9x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 0.2x | XXX | XXX | XXX |
| P/E | (12.7x) | XXX | 2.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 2.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BioStem Technologies Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BioStem Technologies Margins & Growth Rates
BioStem Technologies' revenue in the last fiscal year declined by (84%).
BioStem Technologies' revenue per employee in the last FY averaged $15.1M, while opex per employee averaged $12.8M for the same period.
BioStem Technologies Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (84%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (554%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $15.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $12.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 78% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 85% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BioStem Technologies Public Comps
See public comps and valuation multiples for other Medical Devices and Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BioStem Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| aTyr Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Valerio Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Pliant Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Dicot Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Outset Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioStem Technologies M&A Activity
BioStem Technologies acquired XXX companies to date.
Last acquisition by BioStem Technologies was on XXXXXXXX, XXXXX. BioStem Technologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BioStem Technologies
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioStem Technologies Investment Activity
BioStem Technologies invested in XXX companies to date.
BioStem Technologies made its latest investment on XXXXXXXX, XXXXX. BioStem Technologies invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BioStem Technologies
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BioStem Technologies
| When was BioStem Technologies founded? | BioStem Technologies was founded in 2006. |
| Where is BioStem Technologies headquartered? | BioStem Technologies is headquartered in United States. |
| How many employees does BioStem Technologies have? | As of today, BioStem Technologies has over 20 employees. |
| Is BioStem Technologies publicly listed? | Yes, BioStem Technologies is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of BioStem Technologies? | BioStem Technologies trades under BSEM ticker. |
| When did BioStem Technologies go public? | BioStem Technologies went public in 2008. |
| Who are competitors of BioStem Technologies? | BioStem Technologies main competitors are aTyr Pharma, Valerio Therapeutics, Pliant Therapeutics, Dicot Pharma. |
| What is the current market cap of BioStem Technologies? | BioStem Technologies' current market cap is $84M. |
| What is the current revenue of BioStem Technologies? | BioStem Technologies' last 12 months revenue is $47M. |
| What is the current revenue growth of BioStem Technologies? | BioStem Technologies revenue growth (vs. last FY) is (84%). |
| What is the current EV/Revenue multiple of BioStem Technologies? | Current revenue multiple of BioStem Technologies is 1.3x. |
| Is BioStem Technologies profitable? | No, BioStem Technologies is not profitable. |
| What is the current net income of BioStem Technologies? | BioStem Technologies' last 12 months net income is ($7M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.